Drug discovery and development most frequently fail during clinical trials as in vitro and pre-clinical studies do not effectively translate into success in humans, and attaining regulatory approval, many fail their commercialization goals. Medicinal chemists and scientists in drug discovery can benefit from understanding the cause of these failures. This project, recently approved by the Chemistry and Human Health Division of IUPAC, will create a database of such failures in a specific disease area and evaluate a computational framework to examine the sources of these failures in an objective and comprehensive manner. This is intended to show the value of such a generalized approach for drug discovery and development. Multiple Sclerosis will be the initial target.
For more information and comments, contact Task Group Chair Michael Liebman <firstname.lastname@example.org> • https://iupac.org/project/2019-019-2-700
©2020 IUPAC & De Gruyter. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. For more information, please visit: http://creativecommons.org/licenses/by-nc-nd/4.0/